Get Plus

Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

Ongoing Story· Today

Obesity Drug Wegovy Shows Promise in Young Children in New Study

2 developments

YnetHealth

Weight-Loss Drug Wegovy Shows Promise for Obese Children in New Study

Translated & summarized from Ynet by baba

CenterNeutral tone

Hebrew · 3 newsrooms covering

A new international study found that the weight-loss drug Wegovy significantly reduced obesity in children aged six to 11, with nearly 80% achieving a 10% BMI reduction. Approximately 40% of treated children were no longer considered obese after 68 weeks. Three Israeli medical centers participated in the study, which could lead to new treatment options for young obese children.

The story in 5 lines · by baba

  • Wegovy significantly reduced obesity in children aged 6-11 in a new international study.
  • Nearly 80% of treated children achieved at least a 10% BMI reduction.
  • About 40% of children on Wegovy no longer met obesity criteria after 68 weeks.
  • 16 children from Israel participated in the study across three medical centers.
  • Wegovy is already available in Israel for adolescents aged 12-18.
Weight-Loss Drug Wegovy Shows Promise for Obese Children in New Study
Editorial illustration generated by baba News, not a photograph of the event.

A new international study involving 167 children aged six to 11, including 16 from Israel, suggests that the weekly injection of the weight-loss drug Wegovy (semaglutide) could offer a new treatment option for severely obese young children, leading to significant reductions in Body Mass Index (BMI).

The analysis, which assessed the drug's effectiveness assuming treatment adherence, found that nearly 80% of the children treated with Wegovy achieved at least a 10% decrease in BMI, compared to none in the placebo group. Furthermore, approximately 40% of the children on the drug no longer met the definition of obesity after 68 weeks.

In Israel, three medical centers participated in the research: Schneider, Shamir, and Rambam. Last year, Wegovy was added to Israel's national health basket for treating adolescents aged 12-18, provided they meet specific medical criteria.

YnetCentre · Rishon LeZion

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

HealthTopic

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

Mentioned

Full coverage · 3 outlets
First: Kan News · 55m ago

The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.

Related stories · 1

Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.

Open the Wire